Clinical trial
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic…
NCT03286842 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT03286842 |
|---|---|
| Title | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. |
| Official title | A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations |
| Intervention type | Drug |
| Interventions | Olaparib |
| Enrollment | 256 |
| Start date | Jan 17, 2018 |
| Primary completion | Oct 8, 2021 |
| Completion | Oct 8, 2021 |
| First posted | Sep 19, 2017 |
| Last update posted | Jan 17, 2023 |
| Countries | Bulgaria, Canada, France, Germany, Hungary, Italy, Japan, Poland, Russia, South Korea, Spain, Taiwan and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: